Arcellx, Inc. Income Statement
ACLX / Health Care|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Arcellx, Inc. reported $22M in revenue and $229M in net loss for FY2025. Revenue has declined at a 55.1% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.02 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $22.3M | $107.9M | $110.3M | - | - |
| SG&A Expense | $117.8M | $88.4M | $66.3M | $41.7M | $18.1M |
| R&D Expense | $157.6M | $157.1M | $133.8M | $149.6M | $46.9M |
| Operating Income | -$253.1M | -$137.6M | -$89.9M | -$191.3M | -$65.0M |
| Income Tax | $69.0K | $2.1M | $663.0K | $0 | $0 |
| Net Income | -$228.9M | -$107.3M | -$70.7M | -$188.7M | -$65.0M |
| EPS (Basic) | -$1.47 | -$5.19 | -$5.19 | -$5.19 | -$145.55 |
| EPS (Diluted) | -$1.47 | -$5.19 | -$5.19 | -$5.19 | -$145.55 |
| Shares Outstanding | 54.3M | 52.3M | 44.1M | 36.4M | 446.4K |
| Operating Margin | -1135.6% | -127.5% | -81.5% | - | - |
| Profit Margin | -1027.3% | -99.5% | -64.1% | - | - |